X
RPRX icon

Xponance’s Royalty Pharma RPRX Stock Holding History

Xponance’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.13M Buy
55,752
+3,105
+6% +$162K 0.02% 486
2026
Q1 		$2.53M Buy
52,647
+7,978
+18% +$349K 0.02% 521
2025
Q4 		$1.73M Buy
44,669
+3,415
+8% +$130K 0.01% 565
2025
Q3 		$1.46M Buy
41,254
+331
+0.8% +$12K 0.01% 615
2025
Q2 		$1.47M Buy
40,923
+790
+2% +$26.2K 0.01% 607
2025
Q1 		$1.25M Buy
40,133
+1,437
+4% +$45.5K 0.01% 622
2024
Q4 		$987K Buy
38,696
+5,402
+16% +$143K 0.01% 728
2024
Q3 		$942K Buy
33,294
+1,590
+5% +$44K 0.01% 722
2024
Q2 		$836K Buy
31,704
+606
+2% +$16.8K 0.01% 731
2024
Q1 		$944K Buy
31,098
+17,583
+130% +$518K 0.01% 740
2023
Q4 		$380K Sell
13,515
-4,703
-26% -$129K ﹤0.01% 1012
2023
Q3 		$494K Buy
18,218
+5,090
+39% +$151K 0.01% 896
2023
Q2 		$404K Sell
13,128
-15
-0.1% -$508 0.01% 970
2023
Q1 		$474K Buy
13,143
+63
+0.5% +$2.34K 0.01% 931
2022
Q4 		$517K Buy
13,080
+5,972
+84% +$249K 0.01% 885
2022
Q3 		$286K Buy
7,108
+153
+2% +$6.54K 0.01% 1007
2022
Q2 		$292K Sell
6,955
-16,442
-70% -$674K 0.01% 1015
2022
Q1 		$912K Buy
23,397
+222
+1% +$8.72K 0.02% 626
2021
Q4 		$924K Buy
23,175
+381
+2% +$14.8K 0.01% 638
2021
Q3 		$824K Sell
22,794
-1,378
-6% -$53.6K 0.02% 654
2021
Q2 		$991K Buy
24,172
+9,793
+68% +$417K 0.02% 600
2021
Q1 		$627K Buy
14,379
+9,640
+203% +$457K 0.01% 674
2020
Q4 		$237K Buy
+4,739
New +$201K 0.01% 1007

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Xponance's RPRX Position: Q2 2026 in Review

Xponance increased its Royalty Pharma (RPRX) stake by 5.9% in Q2 2026, buying an estimated $162K and bringing the position to 55,752 shares worth $3.13M. The position accounts for 0.02% of the portfolio, ranked #486.

Xponance first reported a position in RPRX in Q4 2020 and has held it in 23 quarters since. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Xponance held 55,752 shares of Royalty Pharma worth $3.13M as of Q2 2026.
  • Xponance bought 3,105 Royalty Pharma shares in Q2 2026, an estimated $162K.
  • Royalty Pharma made up 0.02% of Xponance's portfolio in Q2 2026, its #486 holding.
  • Xponance first reported a position in Royalty Pharma in Q4 2020 and has held it in 23 quarters since.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.